This appears to be the case as by simply switching from extended, daily administration of the SHIP1 inhibitor, to a pulsatile dosing strategy that allows them to recover from stimulation, improved immune control in three different tumor models [118]. The gene discussed is INPP5D; the disease is neoplasm.